金吾财讯 | 民生证券发研指，近日，巨子生物(02367)独家专利——重组人Ⅳ型胶原蛋白（中国发明专利：ZL202410545206.6）获得国家知识产权局正式授权，这一成果在行业内首次打破传统认知，为Ⅳ型胶原蛋白截短蛋白的应用开辟全新路径。该行指，根据国家药品监督管理局医疗器械技术审评中心(CMDE)发布的《医疗器械优先审批申请审核结果公示（2024年第17号）》，巨子生物的注射用重组胶原蛋白填充剂(受理号：CQZ2402149)属于“列入国家重点研发计划的医疗器械”，符合优先审批情形的项目，拟定予以优先审批。考虑公司具备较强的研发能力和技术优势，看好后续医美产品持续落地对业绩的提振作用。该行表示，公司依托深厚的研发实力，持续打造多品牌矩阵，功效性护肤品产品矩阵持续丰富，医美产品管线未来可期；并通过持续投入研发技术先发优势、精细化运营成功打造大单品的同时持续丰富产品管线、强化宣传力度以不断提升品牌影响力，该行预计2024-2026年经调整净利润为21.31/26.98/32.41亿元，同比增速分别为45.1%/26.6%/20.1%，当前股价对应PE分别为26x、21x、17x，维持“推荐”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.